Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients~* Age greater than or equal to 18 years and less than or equal to 75 years~* Hypertension and metabolic syndrome defined, according to the ATP III/IDF 2005 and ESH/ESC 2007 definitions, as BP greater than or equal to 130/85 mmHg and \<150/95 mmHg (i.e. untreated high normal BP or low range mild hypertension) and at least 2 of the following traits at:~* Abdominal obesity (waist circumference \>102 cm for men and \>88 cm for women)~* Triglyceride level greater than or equal to 150 mg/dL~* High density lipoprotein (HDL) \<40 mg/dL for men and \<50 mg/dL for women~* Fasting blood glucose greater than or equal to 110 mg/dL and \<126 mg/dL (i.e. no type 2 diabetes)~* No anti-hypertensive treatment or treatment with only one anti-hypertensive medication within the last 3 months. Note: treatment with angiotensin II receptor blockers (ARB)or angiotensin-converting enzyme inhibitors (ACE) is not allowed within the last 6 months.~Exclusion Criteria:~* Pregnant or lactating female (prerequisite for female subjects of childbearing potential: adequate contraception)~* Type 1 and type 2 diabetes~* High range mild hypertension (i.e. systolic blood pressure \[SBP\]: 150 - \<160 mmHg and /or diastolic blood pressure \[DBP\]: 95 - \<100 mmHg)~* Moderate (SBP: 160 - 179 mmHg and DBP: 100 - 109 mmHg), severe (SBP: greater than or equal to 180 mmHg and/or greater than or equal to 110 mmHg), or resistant (hypertension resistant to treatment)hypertension~* Secondary hypertension of any aetiology, such as renal disease, pheochromocytoma, or Cushing's syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): A 3-week placebo run-in period.
- 2 (Type: EXPERIMENTAL): Olmesartan medoxomil oral tablets, at lowest study dosage for 52-week double-blind treatment period
- 3 (Type: EXPERIMENTAL): Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 48 weeks.
- 4 (Type: EXPERIMENTAL): Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 4 weeks followed by the highest study dose for 44 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).